Suppr超能文献

药品处方集评估的一个方法:价格指数的应用

A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.

作者信息

Glazer Jacob, Huskamp Haiden A, McGuire Thomas G

机构信息

Tel Aviv University and Boston University.

出版信息

Forum Health Econ Policy. 2012 Mar 30;15(2). doi: 10.1515/1558-9544.1296.

Abstract

Existing economic approaches to the design and evaluation of health insurance do not readily apply to coverage decisions in the multi-tiered drug formularies characterizing drug coverage in private health insurance and Medicare. This paper proposes a method for evaluating a change in the value of a formulary to covered members based on the economic theory of price indexes. A formulary is cast as a set of demand-side prices, and our measure approximates the compensation (positive or negative) that would need to be paid to consumers to accept the new set of prices. The measure also incorporates any effect of the formulary change on plan drug acquisition costs and "offset effects" on non-drug services covered by the plan. Data needed to calculate formulary value are known or can be forecast by a health plan. We illustrate the method with data from a move from a two- to a three-tier formulary.

摘要

现有的医疗保险设计与评估经济方法并不容易应用于私人医疗保险和医疗保险中药物覆盖的多层级药品目录的覆盖决策。本文基于价格指数的经济理论,提出了一种评估药品目录对参保成员价值变化的方法。药品目录被视为一组需求侧价格,我们的衡量方法近似于为使消费者接受新价格集而需支付给他们的补偿(正或负)。该衡量方法还纳入了药品目录变化对计划药品采购成本的任何影响以及对计划所涵盖的非药品服务的“抵消效应”。计算药品目录价值所需的数据是健康计划已知的或可预测的。我们用从两层级药品目录转变为三层级药品目录的数据说明了该方法。

相似文献

1
A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.
Forum Health Econ Policy. 2012 Mar 30;15(2). doi: 10.1515/1558-9544.1296.
3
Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
Pharmacoeconomics. 2019 Oct;37(10):1287-1300. doi: 10.1007/s40273-019-00821-5.
4
Formulary management in the Department of Defense.
J Manag Care Pharm. 2009 Mar;15(2):133-46. doi: 10.18553/jmcp.2009.15.2.133.
5
Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
J Clin Pharm Ther. 2016 Feb;41(1):64-9. doi: 10.1111/jcpt.12349. Epub 2016 Jan 18.
6
Constraints on Formulary Design Under the Affordable Care Act.
Health Econ. 2017 Dec;26(12):e160-e178. doi: 10.1002/hec.3491. Epub 2017 Feb 24.
7
Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
Am J Health Syst Pharm. 2007 Aug 1;64(15 Suppl 10):S3-6; quiz S21-S23. doi: 10.2146/ajhp070252.
8
Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
JAMA Intern Med. 2021 Dec 1;181(12):1605-1611. doi: 10.1001/jamainternmed.2021.5997.
10
Estimating price elasticities of demand for pain relief drugs: evidence from Medicare Part D.
Int J Health Econ Manag. 2024 Dec;24(4):481-515. doi: 10.1007/s10754-024-09382-3. Epub 2024 Aug 2.

引用本文的文献

1
Screening in Contract Design: Evidence from the ACA Health Insurance Exchanges.
Am Econ J Econ Policy. 2019 May;11(2):64-107. doi: 10.1257/pol.20170014.
2
A Welfare Measure of "Offset Effects" in Health Insurance.
J Public Econ. 2012 Jun;96(5-6):520-523. doi: 10.1016/j.jpubeco.2012.02.007. Epub 2012 Feb 25.

本文引用的文献

1
Integrated Insurance Design in the Presence of Multiple Medical Technologies.
Am Econ Rev. 2007 May;97(2):427-432. doi: 10.1257/aer.97.2.427.
2
The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Am Econ Rev. 2010 Mar;100(1):590-607. doi: 10.1257/aer.100.1.590.
3
A Welfare Measure of "Offset Effects" in Health Insurance.
J Public Econ. 2012 Jun;96(5-6):520-523. doi: 10.1016/j.jpubeco.2012.02.007. Epub 2012 Feb 25.
4
Should Medicare adopt the Veterans Health Administration formulary?
Health Econ. 2012 May;21(5):485-95. doi: 10.1002/hec.1733. Epub 2011 Apr 19.
5
Patient Cost-Sharing and Hospitalization Offsets in the Elderly.
Am Econ Rev. 2010 Mar 1;100(1):193-213. doi: 10.1257/aer.100.1.193.
6
Price and welfare effects of a pharmaceutical substitution reform.
J Health Econ. 2010 Dec;29(6):856-65. doi: 10.1016/j.jhealeco.2010.08.003. Epub 2010 Aug 19.
7
Innovation and The Welfare Effects of Public Drug Insurance.
J Public Econ. 2009 Apr 1;93(3-4):541-548. doi: 10.1016/j.jpubeco.2008.11.003.
8
Health spending growth at a historic low in 2008.
Health Aff (Millwood). 2010 Jan-Feb;29(1):147-55. doi: 10.1377/hlthaff.2009.0839.
9
The evolution of medical spending risk.
J Econ Perspect. 2009 Fall;23(4):25-48. doi: 10.1257/jep.23.4.25.
10
Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D.
J Econ Perspect. 2008 Fall;22(4):69-92. doi: 10.1257/jep.22.4.69.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验